Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticoagulant
Anticoagulant